News

Follow us on

Media & Investor Contact

media@kewinc.com

(855) 225-4068

KEW Announces Publication of Analytical Validation Data 06/02/2017

The study demonstrates KEW’s orthogonal validation of somatic genomic variants in solid tumors characterized by CANCERPLEX® with specificity and sensitivity >99.5%. Overall clinical actionability was 93% in...Read Article >

Clinical application of a cancer genomic profiling assay to guide precision medicine decisions 

Read Article >

KEW, Inc. Appoints Jerry Williamson as President and CEO 

Read Article >

Notice of Establishment: New Company, Denka-KEW Genomics 

Read Article >

KEW, Inc. Receives 2016 Best of Cambridge Award 

Read Article >

KEW and the National Foundation for Cancer Research Announce Collaboration to Increase Awareness of CANCERPLEX® 

Read Article >

KEW Announces 2016 ASCO Abstract 

Read Article >

KEW Announces Name Change and Receives College of American Pathologists (CAP) Accreditation 

Read Article >

KEW’s CancerPlex® molecular diagnostic test made available for cancer patients in EU through myTomorrows platform 

Read Article >

KEW Group and Denka Collaborate on a Study to Identify the Benefits of CancerPlex® NGS Testing In Japanese Cancer Patients 10/20/2015

Read Article >

Tom Miller Joins KEW Group as Independent Director 

Read Article >

Genomic Expression and KEW Group to Collaborate 

Read Article >

KEW Group Raises $16.8 Million in Series B Financing 

Read Article >

KEW Group Inc. Announces Completion of Private Financing Round 

Read Article >

KEW Group Launches CancerPlex® Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists 

Read Article >

Events

NGS Webinar

Size does matter. Provide the level of care you would want for your own loved ones.

Read More >

AACR Annual Meeting 2017 – Abstract: Genomic Profiling of the Tumors Harboring Activating EGFR Mutations

EGFR is a receptor tyrosine kinase of the HER/ERBB family and an oncogenic driver, especially for NSCLC, HNSCC and CRC.  EGFR targeted therapies have been successfully used for treating cancer patients harboring activating EGFR mutations.  However a main challenge is acquired drug resistance due to mutations or alternative signaling.  While developing next generation drugs is…

Read More >

Call us

855.225.4068

Email

kewcustomercare@kewinc.com

Location

840 Memorial Drive, 4th Floor Cambridge, MA 02139